Breaks Categories: News

WednesdayNov 12, 2025 12:39 pm

BioMedNewsBreaks — Astiva Health Earns 2026 Senior Choice Gold Award for Excellence in Medicare Advantage Performance and Value

Astiva Health, a rapidly growing Medicare Advantage organization serving California’s diverse senior population, has been awarded the 2026 Senior Choice Gold Award by HealthMetrix Research Inc., recognizing its superior cost-effective coverage and culturally aligned care model. With a 4-star CMS quality rating and more than 38,000 members across the state, Astiva continues to lead in delivering high-value, community-based healthcare—particularly among underserved and multilingual populations in San Diego and Santa Clara. “This recognition reflects our commitment to not only serve, but to understand and elevate the communities we care for,” said Dr. Tri T. Nguyen, co-founder and CEO. To view the…

Continue Reading

WednesdayNov 12, 2025 11:55 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will release its third quarter 2025 financial results before market open on Monday, Nov. 17, 2025, followed by a conference call at 8:30 a.m. ET to discuss corporate, financial, and operational updates. To view the full press release, visit https://ibn.fm/RNyEd About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been…

Continue Reading

TuesdayNov 11, 2025 10:45 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC), and joint venture partner Sapu Bioscience today announced the publication of their review article, “Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential,” in the International Journal of Molecular Sciences (IJMS 2025, 26, 10842; https://doi.org/10.3390/ijms262210842). Authored by Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee, the paper is the first to comprehensively examine nanoparticles exclusively within the 5–15 nm range—an emerging scale poised to redefine nanomedicine. The review highlights how these sub-15 nm systems achieve deeper tissue penetration, reduced organ accumulation, faster renal clearance, and enhanced diffusion across…

Continue Reading

MondayNov 10, 2025 3:11 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida

NRx Pharmaceuticals (NASDAQ: NRXP), announced that its subsidiary, HOPE Therapeutics(TM), has initiated patient care using the Ampa “one day” (ONE-D) protocol for treatment-resistant depression—the first deployment of its kind in Florida and among the first nationwide. The Ampa device combines a single day of transcranial magnetic stimulation (TMS) with physician-prescribed D-cycloserine and lisdexamfetamine, which in peer-reviewed studies have shown response rates of 87% and remission rates of 72% in nonrandomized trials. Under the direction of Medical Director Dr. Rebecca Cohen, HOPE clinics in Sarasota, Naples, and Fort Myers are now offering the protocol, with six Florida locations expected by year-end.…

Continue Reading

MondayNov 10, 2025 12:16 pm

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE

• Lantern’s AI platform “learns, reads, models, and predicts” to identify new drugs and indications • CEO Panna Sharma says AI is compressing development timelines and cost structures across oncology  Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer drug developer, is using large-scale machine learning to discover new therapies, reposition existing molecules, and target high-unmet-need oncology indications. CEO Panna Sharma told FintechTV the company’s proprietary platform now self-learns, reads scientific papers, models molecules, predicts patient response, and suggests new indications — significantly reducing the time and cost of drug development. Lantern has three clinical-stage oncology candidates, including a Phase 2 trial for…

Continue Reading

FridayNov 07, 2025 10:05 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company advancing treatments for rare diseases with unmet medical need, reported third quarter 2025 results and outlined upcoming milestones, including top-line Phase 2a results for SGX302 in psoriasis and an enrollment update for its confirmatory Phase 3 HyBryte(TM) study in cutaneous T-cell lymphoma (CTCL). CEO Christopher J. Schaber, PhD, confirmed that the first Data Monitoring Committee review found no safety concerns for HyBryte(TM), maintaining a consistent safety profile across trials. With $10.5 million in cash as of Sept. 30, 2025, Soligenix expects its operating runway to extend through 2026 while evaluating strategic options to…

Continue Reading

ThursdayNov 06, 2025 12:05 pm

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments

  Lantern Pharma (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR(R) platform, will host a webcast at 9 a.m. ET (6 a.m. PT) on Thursday, Nov. 13, 2025, to review third-quarter operating and financial results. President and CEO Panna Sharma and other members of the management team will discuss quarterly performance, clinical trial progress, and upcoming milestones for the company’s AI and machine learning initiatives. To view the full press release, visit https://ibn.fm/yghCi About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and…

Continue Reading

WednesdayNov 05, 2025 11:27 am

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) Subsidiary PharmcoRx Awarded Multi-State Prescription Fulfillment Contract From DevotedDOc 

NextPlat (NASDAQ: NXPL, NXPLW), a global provider of healthcare and technology solutions through e-commerce and retail channels, announced that its PharmcoRx subsidiary has secured an exclusive multi-state prescription fulfillment services contract from DevotedDOc, a virtual medical group specializing in urgent care, Medication-Assisted Treatment for opioid use disorder, and compounded alternatives to GLP-1 therapies for weight loss and hormone replacement therapy. PharmcoRx will begin serving patients in Florida and Georgia in November, with plans to expand nationally across its licensed territories. Vice President of Healthcare Operations Birute Norkute said the partnership underscores NextPlat’s commitment to improving access to rapid, affordable, and…

Continue Reading

WednesdayNov 05, 2025 9:00 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Initiated With Buy Rating and $4 Price Target by Roth Capital

HeartBeam (NASDAQ: BEAT) has been initiated with a Buy rating and $4 price target by Roth Capital Partners, which highlighted the company’s near-term catalyst of expected FDA clearance for its groundbreaking 12-lead ECG synthesis software. The report cites BEAT’s compact, credit card-sized, cable-free device capable of synthesizing a full 12-lead ECG as a breakthrough in remote cardiac monitoring. Roth’s analysts, led by Kyle Bauser, Ph.D., view BEAT as undervalued given its strong clinical validation, lean cost structure, and potential to redefine how arrhythmias are detected and treated in decentralized care environments. Roth’s initiation notes that HeartBeam’s pivotal VALID-ECG study (n=198)…

Continue Reading

MondayNov 03, 2025 2:06 pm

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) to Announce Q3 2025 Financial Results on Nov. 13 

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels, will release its financial results for the quarter ended Sept. 30, 2025, before market open on Nov. 13, 2025. CEO and President of Global Operations David Phipps, CFO Amanda Ferrio, and Vice President of Healthcare Operations Birute Norkute will host a conference call that day at 8:30 a.m. ET to discuss the results and other recent developments. To view the full press release, visit: https://ibn.fm/9fSPg About NextPlat Corp. Nextplat is a global consumer products and services company providing healthcare…

Continue Reading